Sevacertinib for solid tumors with HER2 mutations
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study tests an oral tablet called sevacertinib in people with solid tumors (not lung cancer) that have a HER2 mutation. It aims to see how well the drug works and how safe it is for people who have tried other treatments or have no good options left.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor cancer (not lung cancer) that has a specific HER2 mutation.
- You are at least 18 years old.
- You have tried standard treatments for your cancer type, or there are no good standard options for you.
- You have at least one tumor that can be measured on a scan.
- You have not received a previous HER2 tyrosine kinase inhibitor (TKI) treatment.
- You do not have active brain tumors that are growing or causing symptoms.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental drug called VVD-159642 in people with advanced solid tumors that have specific genetic changes (RAS or EGFR alterations, or HER2 overexpression). The goal is to see if the drug is safe and tolerable.
This trial tests an investigational drug (SHR-4602) alone or with other treatments for advanced solid tumors that have HER2. The goal is to see if it can shrink or control the cancer.
This trial tests a new drug called Mocertatug Rezetecan for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called B7-H4 on cancer cells to try to slow or shrink the tumor.
This trial provides access to an investigational pill called sevabertinib (BAY 2927088) for people with advanced non-small cell lung cancer that has a HER2 mutation. It aims to see if this medication can help control the cancer when other treatments have stopped working.
This trial compares a new targeted drug called sevabertinib against standard chemotherapy plus immunotherapy for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation. The goal is to see if sevabertinib works better and is safe.
This trial tests a new drug, VRN101099, for people with HER2-positive or HER2-mutated cancers that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow cancer growth.
Hear when a new HER2 Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.